arrow
L

Longlong Luo

Shenyang Pharmaceutical University
H指数:14
被引数:611

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pan-filovirus activity of an IGF2-fused monoclonal antibody: Impairment by IGF1R cross-engagement and rescue via IGF2 Y27L mutation

融合IGF2的单克隆抗体对泛丝状病毒的活性:被IGF1R交叉结合所抑制,并通过IGF2 Y27L突变获得拯救

2026-07-010
PRE
Physics-Informed Artificial Intelligence Design of Picomolar Nanobodies Enables Deep Tumor Penetration and High-Contrast Imaging

皮摩尔纳米抗体的物理信息人工智能设计可实现深度肿瘤穿透和高对比度成像

Research
IF10.7
2026-06-240
OA
A high-affinity CEA-targeted nanobody for 68Ga PET imaging and 177Lu-based radioisotope therapy: preclinical and first-in-human evaluation

一种高亲和力CEA靶向纳米抗体用于68Ga PET成像和177Lu为基础的放射性核素治疗:临床前和首次人体评估

2025-11-240
OA
A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy

鼻咽癌的三联治疗策略:适配体引导的脂质体化疗、工程化NK细胞和Fc增强型PD-L1抗体疗法

2025-10-140
OAAI
Clostridium perfringens alpha toxin drives pathological NETosis via immature neutrophil mobilization and functional reprogramming

梭状芽孢杆菌α毒素通过未成熟中性粒细胞的动员和功能重编程驱动病理性NETosis

2025-09-120
OAAI
Novel Quaternary Ammonium Salt-Linked STING Agonist Antibody-Drug Conjugate: Synergistic Activation of Tumor Immunity with Mitigated Off-Target Toxicity

新型季铵盐连接的STING激动剂抗体药物偶联物:协同激活肿瘤免疫并降低脱靶毒性

2025-06-100
OAAI
Unveiling novel insights into human IL-6-IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

通过3D计算机引导的对接和系统的位点诱变揭示人类IL-6-IL-6R相互作用位点的新见解

2024-08-070
OAAI
Construction of functional neural network tissue combining CBD-NT3-modified linear-ordered collagen scaffold and TrkC-modified iPSC-derived neural stem cells for spinal cord injury repair

CBD-NT3-modified线性有序胶原支架与TrkC修饰的iPSC源性神经干细胞联合构建脊髓损伤修复功能神经网络

2024-05-016
OAAI